The U.S. FDA has granted Datar Cancer Genetics Inc. a breakthrough device designation for Trinetra-Glio, a blood test to help in the diagnosis of brain tumors.
Engineers from Washington University in Saint Louis are developing a novel imaging technique for evaluating the use of alpha-particle emitting radiopharmaceutical therapy in tumors and other radiation-sensitive organs of the body. They have tested a low-count quantitative single-photon emission computed tomography (LC-QSPECT) method to provide reliable measurements of the radionuclide uptake in lesions and at-risk organs after its administration.
Bertis Co. Ltd.’s artificial intelligence (AI)-based diagnosis model is able to detect diseases, such as cancers, with more than 95% accuracy, according to preliminary testing results reported at the Human Proteome Organization 2022 meeting in Cancun, Mexico on Dec. 8.
Pancreatic cancer is the deadliest of cancers with just one in nine patients surviving five years after diagnosis. The low rate of survival largely results from the late stage at which the cancer is first detected, as 65% patients are not diagnosed until the disease has metastasized. Bluestar Genomics Inc. hopes it has developed an assay that can detect the cancer much sooner, allowing patients and their physicians to get ahead of the malignancy well before it spreads.
The high and specific expression of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) in multiple types of tumors makes it an ideal target for drug delivery.
Researchers from Shouyao Holdings (Beijing) Co. Ltd. presented the discovery of novel Wee1-like protein kinase inhibitors being investigated as agents for the treatment of cancer.
Haystack Oncology Inc. has launched with a $56 million series A round to commercialize technology using circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) following surgery for early-stage cancers.
Trisalus Life Sciences Inc. agreed to merge with Medtech Acquisition Corp. (MTAC) in a deal that allows the drug/device company’s management to meet three out of three goals: quick cash, retained control and faster completion of key clinical trials.
Samantree Medical SA has published clinical data demonstrating a significant reduction in re-operations in breast-conserving surgery using its novel ultra-fast confocal microscopy technology. The study on its medical imaging platform, the Histolog scanner, has just been published in The Breast.
HKSH Medical Group (HKSH) has adopted droplet digital polymerase chain reaction (ddPCR) for minimal residual disease (MRD) monitoring to track the status of patients with leukemia.
